One mg of glucagon was given subcutaneously to eight patients with active acromegaly.
It is known that active acromegalic patients show paradoxical or abnormal GH response to some drugs Liuzzi et al., 1974) or substances (Irie and Tsushima, 1972; Rubin et al., 1973) . Subcutaneous administration of glucagon produces a significant rise in plasma GH in normal subjects (Mitchell et al., 1969; Cain et al., 1970) .
It is interesting to examine if glucagon could induce a paradoxical response in serum GH in patients with active acromegaly. This report describes a suppressive effect of glucagon on serum GH in active acromegalic patients.
Eight active acromegalic patients (5 men and 3 women) were studied.
After an overnight fast, 1mg of glucagon (Novo Co. Ltd.) was injected subcutaneously. Blood sample was collected through the cubital vein, before and 30, 60, 90, 120, 150, and 180 min after the glucagon injection. As a control study, an oral glucose tolerance test was performed in the same patients.
Serum GH levels were determined by radioimmunoassay for GH (Schalch and Parker, 1964) in which the coefficiencies of intra-assay variation and inter-assay variation were 6.7% and 8.0%, respectively. Blood glucose levels were determined by an auto-analyser method (Hoffman, 1937) .
The results are summarized in Table 1 and 2. In seven out of eight patients serum GH levels decreased rapidly within 30 min after the injection of glucagon by 25.8 58.4%. Two patients (K. S., H. A.) showed an elevation of serum GH levels following an initial reduction. (Table 1) Although blood glucose levels increased significantly after the injection of glucagon in all eight patients, one patient (E. S.) failed to show a decrease in serum GH levels to the glucagon injection.
On the other hand, an oral administration et al.
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Japon. December 1975 of 50g glucose elicited a similar increase patients no early suppression of serum GH in blood glucose levels to that after the levels was observed following the oral glucagon injection, while in all eight glucose administration. (Table  2 ) The data suggest that the subcutaneous administration of glucagon induced a rapid decrease in serum GH levels in most of acromegalic patients.
In normal subjects glucagon causes GH release between 120 and 180min after its subcutaneous injection, while in active acromegalic patients glucagon decreased the serum GH levels as soon as 30min after its injection. Thus the mechanism by which glucagon exerts GH release in acromegalic patients could be different from that exerted GH release in normal subjects. It is unlikely that the decrease in serum GH levels observed after the glucagon injection was spontaneous GH levels was observed at 30min after the administration of glucose in all patients.
It is conceivable that the decrease in serum GH levels induced by glucagon in patients with active acromegaly could be related to the increase in blood glucose levels. However, an oral administration of 50g glucose which caused a similar increase in blood glucose levels to that after the glucagon injection elicited no early suppression in serum GH levels in all patients with active acromegaly (Fig. 1) . Therefore, it is suggested that the early GH suppression induced by glucagon might not be mediated by the increase in blood glucose levels. Mitchell et al (1971) suggested that glucagon might act as an alpha-adrenergic stimulant on the hypothalamus or the pituitary gland, since glucagon can bring about a release of catecholamines from the adrenal medulla. Likewise, it is possible that glucagon stimulates the release of catecholamines from the neurons in the hypothalamus.
It has been reported that dopaminergic stimulation causes an inhibition of GH release in acromegalic patients . Increased release of catecholamines, especially dopamine, could suppress GH release by its direct action on the pituitary gland and suppressive effect would be observed when the basal serum levels of GH have already elevated.
It is also conceivable that in acromegalic patients responses of the GHreleasing factor in the hypothalamus and/ or of GH release on the pituitary gland to catecholamines could be different from those in normal subjects. his help in preparing this manuscript. Technical assistance by Miss. Yoshioka is also gratefully acknowledged.
Glucagon or Glucose Fig. 1 . Mean serum GH levels indicated as percentage of basal GH levels (lower part), and blood glucose levels (upper part) before and after subcutaneous injection of 1mg glucagon or oral administration of 50g glucose in 8 patients with active acromegaly.
Horizontal lines denote standard error of the mean.
